2-hydroxy-butyric acid isobutyl ester | 116723-95-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-hydroxy-butyric acid isobutyl ester
• 英文别名: 2-Hydroxy-buttersaeure-isobutylester；2-hydroxy-butanoic acid, 2-methylpropyl ester；Isobutyl 2-hydroxybutyrate；2-methylpropyl 2-hydroxybutanoate
• CAS: 116723-95-6
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: FTYMELMGTRSDDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-hydroxy-butyric acid isobutyl ester 、 苯甲酰氯 生成 2-benzoyloxy-butyric acid isobutyl ester
  参考文献：
  名称：

  Guye; Jordan, Bulletin de la Societe Chimique de France, 1896, vol. <3>15, p. 495

  摘要：

  DOI：
• 作为产物：
  描述：

  异丁醇 、 alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 2-hydroxy-butyric acid isobutyl ester
  参考文献：
  名称：

  Guye; Jordan, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1895, vol. 120, p. 632

  摘要：

  DOI：

文献信息

• Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents
  申请人：Huse Klaus

  公开号：US20080300303A1

  公开（公告）日：2008-12-04

  The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according to formula (I) for the treatment of diseases associated with increased glycolytic metabolism. In one embodiment, the disease is a fungal infection.

  本发明涉及式（I）的物质，其中X是O或S; R1-R4在权利要求中定义为乙醛酸酯酶I和/或II的抑制剂，包含一个或多个式（I）化合物的制药组合物以及使用一个或多个式（I）化合物治疗与增加的糖酵解代谢相关的疾病。在一种实施方式中，该疾病是真菌感染。
• Novel Crystalline Forms of Antidiabetic Compounds
  申请人：Zhao Dalian

  公开号：US20080221198A1

  公开（公告）日：2008-09-11

  Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

  两种吲哚化合物与苯氧烷基羧酸基团相连的新晶体形式是选择性PPARγ部分激动剂，可用于治疗2型糖尿病、高血糖、肥胖症、血脂异常和代谢综合征。新晶体形式包括一种化合物的结晶自由酸二水合物和结晶自由酸无水物，以及第二种化合物的自由酸和钠盐的几种晶体形式。本发明还涉及包含这些新晶体形式的制药组合物、制备晶体形式及其制药组合物的工艺，并将晶体形式用于治疗2型糖尿病和其他PPARγ调节疾病。
• Crystalline forms of antidiabetic compounds
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07683092B2

  公开（公告）日：2010-03-23

  Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

  两种与苯氧基烷基羧酸基团相连的吲哚化合物的新晶体形式是选择性PPARγ部分激动剂，可用于治疗2型糖尿病、高血糖、肥胖症、血脂异常和代谢综合征。新晶体形式包括一种化合物的结晶自由酸二水合物和结晶自由酸无水物以及第二种化合物的自由酸和钠盐的多种晶体形式。本发明还涉及包含这些新晶体形式的药物组合物、制备晶体形式及其药物组合物的过程以及晶体形式在治疗2型糖尿病和其他PPARγ调节疾病中的用途。
• Silicon-containing antireflective coating forming composition, silicon-containing antireflective coating, substrate processing intermediate, and substrate processing method
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：EP1788012A1

  公开（公告）日：2007-05-23

  A composition for forming an antireflective coating for use in a photolithography process using exposure light of up to 200 nm comprises a silicon-containing polymer obtained through hydrolytic condensation of a silicon-silicon bond-containing silane compound having formula: R(6-m)Si2Xm wherein R is a monovalent hydrocarbon group, X is alkoxy, alkanoyloxy or halogen, and m is 3 to 6. The composition allows the overlying photoresist film to be patterned to a satisfactory profile and has a high etching selectivity relative to organic material so that a substrate can be processed at a high accuracy.

  一种用于形成抗反射涂层的组合物，可在使用 200 纳米以下曝光光的光刻工艺中使用，该组合物包括一种通过水解缩合含硅-硅键的硅烷化合物而获得的含硅聚合物，该硅烷化合物的化学式如下： R(6-m)Si2Xm 其中 R 是一价烃基，X 是烷氧基、烷酰氧基或卤素，m 是 3 至 6：R(6-m)Si2Xm 其中 R 为一价烃基，X 为烷氧基、烷酰氧基或卤素，m 为 3 至 6。该组合物可将上覆的光刻胶膜图案化为令人满意的轮廓，并且相对于有机材料具有较高的蚀刻选择性，从而可对基底进行高精度加工。
• NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS
  申请人：Merck & Co., Inc.

  公开号：EP1858844A1

  公开（公告）日：2007-11-28